콘텐츠로 건너뛰기
Merck
  • Erythroid induction of chronic myelogenous leukemia K562 cells following treatment with a photoproduct derived from the UV-A irradiation of 5-methoxypsoralen.

Erythroid induction of chronic myelogenous leukemia K562 cells following treatment with a photoproduct derived from the UV-A irradiation of 5-methoxypsoralen.

ChemMedChem (2010-07-21)
Alessia Salvador, Stefano Dall'Acqua, Manlio Sutera Sardo, Sergio Caffieri, Daniela Vedaldi, Francesco Dall'Acqua, Monica Borgatti, Cristina Zuccato, Nicoletta Bianchi, Roberto Gambari
초록

Induction of terminal erythroid differentiation can be an efficient strategy to inhibit proliferation of chronic myelogenous leukemia cells. Psoralens, well-known photo-chemotherapeutic agents, were found to be efficient at inducing erythroid differentiation of K562 cells, an in vitro cell line isolated from the pleural effusion of a patient with chronic myelogenous leukemia in blast crisis. The effects of crude pre-irradiated solutions of 5-methoxypsoralen on erythroid differentiation of human leukemic K-562 cells were evaluated. The major photoproduct was characterized and analyzed, and it was found to induce erythroid differentiation of K562 cells and inhibit NF-kappaB/DNA interactions.

MATERIALS
제품 번호
브랜드
제품 설명

Supelco
Bergapten, analytical standard
Sigma-Aldrich
5-Methoxypsoralen, 99%